异甘草酸镁联合恩替卡韦对慢性乙型肝炎HBeAg阳性患者治疗指标的影响研究

发布时间：2019-07-10 21:04

【摘要】：目的探讨异甘草酸镁联合恩替卡韦对慢性乙型肝炎HBeAg阳性患者治疗指标的影响,从中寻找现阶段更理想的治疗方案。方法将2013年1月-2014年6月在无锡市第五人民医院肝病科住院或门诊治疗的慢性乙型肝炎HBeAg阳性患者96例,随机分为两组,其中治疗组51例患者给予异甘草酸镁200mg静脉滴注,每日1次,采用较长疗程逐步减少用药次数的方法给药,疗程16周,同时给以恩替卡韦片0.5mg空腹口服,每日1次,疗程亦为16周;对照组45例患者给予恩替卡韦片0.5mg空腹口服,每日1次,疗程16周。结果治疗组在治疗后HBV-DNA阴转率为90.2%,HBeAg阴转率为23.5%,HBeAg转换率为21.6%,均优于对照组的84.4%、20.0%和17.8%,差异有统计学意义(P0.05);两组患者在治疗前后肝纤维化指标均有改善,但治疗后组间比较,治疗组肝纤维化指标改善优于对照组,差异有统计学意义(P0.05)。结论异甘草酸镁联合恩替卡韦治疗慢性乙型肝炎HBeAg阳性患者能获得更高的HBV-DNA阴转率、HBeAg阴转率/HBeAg转换率以及能更好的改善肝纤维化程度,为现阶段更为理想治疗方案。
[Abstract]:Objective to investigate the effect of magnesium isoglycyrrhizinate combined with entecavir on the treatment indexes of HBeAg positive patients with chronic hepatitis B (CHB), and to find a more ideal treatment scheme at the present stage. Methods from January 2013 to June 2014, 96 patients with HBeAg positive chronic hepatitis B were randomly divided into two groups. 51 patients in the treatment group were treated with magnesium isoglycyrrhizinate 200mg intravenously once a day. The treatment group was given magnesium isoglycyrrhizinate 200mg intravenously once a day. The course of treatment was 16 weeks, and 0.5mg tablets were given oral on an empty stomach once a day. The course of treatment was also 16 weeks. 45 patients in the control group were treated with enticawe tablets 0.5mg on an empty stomach once a day for 16 weeks. Results after treatment, the negative conversion rate of HBV-DNA in the treatment group was 90.2%, the negative conversion rate was 23.5%, and the conversion rate was 21.6%, which was better than that in the control group (84.4%, 20.0% and 17.8%). The difference was statistically significant (P 0.05). The indexes of hepatic fibrosis in the two groups were improved before and after treatment, but after treatment, the improvement of hepatic fibrosis index in the treatment group was better than that in the control group, the difference was statistically significant (P 0.05). Conclusion magnesium isoglycyrrhizinate combined with entecavir can obtain higher HBV-DNA negative conversion rate, HBeAg negative conversion rate / HBeAg conversion rate and improve the degree of hepatic fibrosis in patients with HBeAg positive chronic hepatitis B. it is a more ideal treatment scheme at this stage.
【作者单位】：无锡市第五人民医院肝病科;
【基金】：江苏省科技厅研究基金资助项目(JS0312111)
【分类号】：R512.62

【参考文献】